0.1916
price down icon0.26%   -0.0005
after-market Dopo l'orario di chiusura: .19 -0.0016 -0.84%
loading
Precedente Chiudi:
$0.1921
Aprire:
$0.181
Volume 24 ore:
818.60K
Relative Volume:
2.74
Capitalizzazione di mercato:
$8.01M
Reddito:
$20.27M
Utile/perdita netta:
$-63.80M
Rapporto P/E:
-0.1261
EPS:
-1.52
Flusso di cassa netto:
$-68.35M
1 W Prestazione:
-41.94%
1M Prestazione:
-52.11%
6M Prestazione:
-79.72%
1 anno Prestazione:
-90.02%
Intervallo 1D:
Value
$0.17
$0.224
Intervallo di 1 settimana:
Value
$0.17
$0.37
Portata 52W:
Value
$0.17
$2.0497

Carisma Therapeutics Inc Stock (CARM) Company Profile

Name
Nome
Carisma Therapeutics Inc
Name
Telefono
(267) 491-6422
Name
Indirizzo
3675 MARKET STREET, PHILADELPHIA
Name
Dipendente
68
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
CARM's Discussions on Twitter

Confronta CARM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CARM
Carisma Therapeutics Inc
0.1916 8.01M 20.27M -63.80M -68.35M -1.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-12 Downgrade Robert W. Baird Outperform → Neutral
2024-12-10 Downgrade BTIG Research Buy → Neutral
2024-04-11 Iniziato BTIG Research Buy
2023-10-03 Iniziato CapitalOne Overweight
2023-07-06 Iniziato Evercore ISI Outperform
2023-05-31 Aggiornamento Jefferies Hold → Buy
2023-05-24 Iniziato H.C. Wainwright Buy
2023-04-14 Iniziato Robert W. Baird Outperform
Mostra tutto

Carisma Therapeutics Inc Borsa (CARM) Ultime notizie

pulisher
02:34 AM

Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace

02:34 AM
pulisher
Apr 03, 2025

Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MyChesCo

Apr 03, 2025
pulisher
Apr 02, 2025

Philly’s Carisma Therapeutics slashed its workforce to 6 from 46 for sale or wind down - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Carisma Therapeutics (NASDAQ:CARM) Price Target Lowered to $1.00 at D. Boral Capital - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Carisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis Treatment - MSN

Apr 01, 2025
pulisher
Mar 31, 2025

Penn spinout Carisma Therapeutics lays off 84% of its staff, explores possible sale - The Business Journals

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Provides Corporate Updates - Citizen Tribune

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Explores Sale Options as Company Halts R&D Programs - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st

Mar 28, 2025
pulisher
Mar 28, 2025

Carisma Therapeutics (CARM) to Release Earnings on Monday - Defense World

Mar 28, 2025
pulisher
Mar 22, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Analysts - Defense World

Mar 22, 2025
pulisher
Mar 13, 2025

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annua - GuruFocus.com

Mar 13, 2025
pulisher
Feb 25, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

Feb 25, 2025
pulisher
Feb 22, 2025

Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference - MSN

Feb 22, 2025
pulisher
Feb 19, 2025

Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 - Quantisnow

Feb 19, 2025
pulisher
Feb 19, 2025

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Quantisnow

Feb 19, 2025
pulisher
Feb 11, 2025

Carisma Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Conference - MSN

Feb 11, 2025
pulisher
Feb 05, 2025

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - Quantisnow

Feb 05, 2025
pulisher
Feb 04, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update - Defense World

Feb 04, 2025
pulisher
Jan 31, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

Jan 31, 2025
pulisher
Jan 30, 2025

Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga

Jan 30, 2025
pulisher
Jan 22, 2025

BTIG Downgrades Carisma Therapeutics (CARM) - MSN

Jan 22, 2025
pulisher
Jan 18, 2025

Evercore ISI Group Downgrades Carisma Therapeutics (CARM) - MSN

Jan 18, 2025
pulisher
Jan 18, 2025

Barclays PLC Has $539,000 Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World

Jan 18, 2025
pulisher
Jan 14, 2025

Carisma Therapeutics (NASDAQ:CARM) Given “Buy” Rating at D. Boral Capital - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

Geode Capital Management LLC Lowers Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World

Jan 14, 2025
pulisher
Jan 11, 2025

Carisma Therapeutics faces Nasdaq delisting over share price - Investing.com India

Jan 11, 2025
pulisher
Jan 10, 2025

Carisma Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada

Jan 10, 2025
pulisher
Jan 06, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Rating of “Hold” from Analysts - Defense World

Jan 06, 2025
pulisher
Jan 03, 2025

Barclays PLC Grows Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World

Jan 03, 2025
pulisher
Dec 30, 2024

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023 - GuruFocus.com

Dec 30, 2024
pulisher
Dec 27, 2024

4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology - Quantisnow

Dec 27, 2024
pulisher
Dec 26, 2024

Carisma Therapeutics Appoints Interim VP of Finance - TipRanks

Dec 26, 2024
pulisher
Dec 20, 2024

Carisma Therapeutics Refocuses Strategy, Reduces Workforce Amid Pipeline Reprioritization - MSN

Dec 20, 2024
pulisher
Dec 18, 2024

Carisma downgraded by H.C. Wainwright to neutral - MSN

Dec 18, 2024
pulisher
Dec 17, 2024

Carisma Therapeutics (NASDAQ:CARM) Given Neutral Rating at HC Wainwright - Defense World

Dec 17, 2024
pulisher
Dec 16, 2024

HC Wainwright & Co. Downgrades Carisma Therapeutics (CARM) - MSN

Dec 16, 2024
pulisher
Dec 16, 2024

Carisma shares downgraded to neutral after program halt - Investing.com

Dec 16, 2024

Carisma Therapeutics Inc Azioni (CARM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):